Michael Boyer, MD

Sydney Cancer Centre, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia

Michael Boyer is a medical oncologist at the Sydney Cancer Centre / Royal Prince Alfred Hospital (RPAH) in Sydney, and Chief Clinical Officer of the Chris O’Brien Lifehouse at RPA, an integrated cancer centre currently under construction on the RPAH campus. He is also a Clinical Professor in the Central Clinical School, University of Sydney. Professor Boyer is a member of the University of Sydney Cancer Research Network.

Following his specialty training in medical oncology at Royal Prince Alfred and Westmead Hospitals, Professor Boyer was a Research Fellow and Clinical Fellow at the Ontario Cancer Institute and Princess Margaret Hospital in Toronto, Canada, where he completed his PhD on cell biology. He was the recipient of a Medical Research Council of Canada Research Fellowship. He has been on the senior staff of the Sydney Cancer Centre and Royal Prince Alfred Hospital since 1993. In addition to his clinical roles, he has held senior administrative positions during that time including Head of Department of Medical Oncology, Director of Sydney Cancer Centre, and Area Director of Cancer Services. He played a central role in the development and implementation of the business case for an integrated cancer centre on the RPAH campus, and is on the board of directors of Lifehouse at RPA, as the centre is now known.

His clinical interests are in the management of thoracic malignancies and head and neck cancers, His research training includes a laboratory PhD at the University of Toronto between 1990 and 1993. His more recent major research interest is in clinical trials of new agents in the management of lung cancer and mesothelioma. He has career grant income totaling $14.9M and is one of five grant holders of a Cancer Institute NSW Translational Cancer Centre Grant. He is the author of over 125 publications, has given numerous national and international presentations, both invited and selected from abstract submission, and is actively involved in the lung cancer community. He chaired the scientific advisory committee of the Australasian Lung Cancer Trials Group between 2004 and 2011. In the past, within IASLC, he has been a member of the Fellowship Committee and chaired the Bylaws Committee, and is now the conference Co-President for the upcoming 15th World Conference on Lung Cancer to be held in Sydney in 2013.